New combo therapy aims to boost liver cancer surgery success

NCT ID NCT05701488

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the combination, then undergo surgery. The main goal is to check for serious side effects, while also looking at how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab, tremelimumab, and yttrium-90 radioactive microspheres
What this could lead to
If successful, this could point toward a safer and more effective way to shrink liver tumors before surgery, potentially improving outcomes for patients with resectable hepatocellular carcinoma.
What could go wrong
This is a very early phase 1 trial with only 20 participants, so results may not apply broadly. The combination of immunotherapy and radiation carries risks of serious side effects, and the treatment may not improve surgical outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.